0001209191-22-039314.txt : 20220624 0001209191-22-039314.hdr.sgml : 20220624 20220624180031 ACCESSION NUMBER: 0001209191-22-039314 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220623 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HUNT RONALD CENTRAL INDEX KEY: 0001247851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 221041181 MAIL ADDRESS: STREET 1: C/O CREDIT SUISSE 1ST BOSTON PRV EQY STREET 2: 11 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-06-23 0 0001659323 Iterum Therapeutics plc ITRM 0001247851 HUNT RONALD C/O ITERUM THERAPEUTICS PLC FITZWILLIAM COURT, FL. 1, LEESON CLOSE DUBLIN 2 L2 IRELAND 1 0 0 0 Ordinary Shares 2022-06-23 2022-06-23 4 M 0 36798 A 42501 D Ordinary Shares 1071688 I By New Leaf Ventures III, L.P. Ordinary Shares 384615 I By New Leaf Biopharma Opportunities II, L.P. Restricted Share Units 0.00 2022-06-23 2022-06-23 4 M 0 36798 0.00 D Ordinary Shares 36798 0 D Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any. These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any. On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022. /s/ Ronald M. Hunt 2022-06-24